You are here

A novel vaccine against mosquito-borne Zika virus based on mosquito salivary gland protein AgBR1

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R42AI142846-03
Agency Tracking Number: R42AI142846
Amount: $1,967,842.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: NIAID
Solicitation Number: PA20-265
Solicitation Year: 2020
Award Year: 2022
Award Start Date (Proposal Award Date): 2022-08-18
Award End Date (Contract End Date): 2025-07-31
Small Business Information
BOX 8175
New Haven, CT 06530-0175
United States
DUNS: 142406110
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (203) 785-4140
Business Contact
Phone: (203) 393-9439
Research Institution
NEW HAVEN, CT 06520-8327
United States

 Nonprofit College or University

Arboviruses present a constant threat to human and animal health worldwide. They are transmitted by
hematophagous arthropods, primarily mosquitoes. One of them, Aedes aegypti, is the primary vector of several
widely spread arboviruses such as Zika, dengue and West Nile viruses, and for most of them, human-licensed
vaccines do not exist or are suboptimal. These pathogens are transmitted into the host skin together with saliva
during feeding. This saliva contains over one hundred unique proteins which can modulate many physiological
functions, facilitating blood feeding.
It has been shown that many salivary proteins enhance infectivity and pathogenesis of arboviruses by modulating
immune responses at the bite site. The development of blocking therapies against them could be a good
approach to reduce viral spread in the infected host. This approach may also overcome issues associated with
the use of viral antigens as a vaccine targets, due to their high variability or the possibility of induction of antibody-
dependent enhancement episodes.
In Phase I, a proof-of-principle has been established for a novel strategy of prophylaxis, targeting one salivary
protein secreted in A. aegypti saliva, AgBR1, in which passively and actively immunized immunocompromised
murine models were partially protected against Zika virus transmitted via mosquito bites. The degree of
protection correlated with the antibody titer reached in the immunized animals. However, the use of
immunocompromised models has some limitations, such as the weakness of the antibody response, a fact that
limits the maximum protection that can be achieved. In this Phase II application, we will define, optimize, and
validate a vaccination regimen.
We will circumvent the limitations of the immunocompromised animal model by conducting immunizations in
immunocompetent murine hosts. We will test the degree of protection achieved by transferring antibodies and/or
immune cells to immunocompromised mice, also studying the role of the cellular branch of the immune response
against ZIKV infection, as the cellular immune response against mosquito salivary antigens is poorly understood.
In addition, we will perform these vaccination studies in guinea pigs and hamsters, to demonstrate that a strong
immune response against AgBR1 can be elicited in species other than mice. We will develop a guinea pig and
a hamster model of Zika infection transmitted by A. aegypti mosquito bites, and we will test the immunization
efficacy of our vaccine candidates. Lastly, we will analyze the potential efficacy of our vaccine against other Zika-
related flaviviruses, such as DENV and WNV, with the aim to generate a pan-flaviviral vaccine candidate which
could be used alone or in conjunction with pathogen-specific vaccines.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government